Patient demographics and baseline characteristics

CharacteristicN = 51
Age, n (%)
  <65 years28 (54.9)
  ≥65 years23 (45.1)
 Median (range), years64.0 (31–84)
Sex, n (%)
 Male34 (66.7)
 Female17 (33.3)
Race, n (%)
 White35 (68.6)
 Asian2 (3.9)
 American Indian or Alaskan1 (2.0)
 Black or African American1 (2.0)
 Other12 (23.5)
ECOG performance status, n (%)
 025 (49.0)
 126 (51.0)
Site of primary tumor, n (%)
 Cutaneous28 (54.9)
 Ocular16 (31.4)
 Mucosal2 (3.9)
 Othera5 (9.8)
Time from initial diagnosis to study entry, years
 Median4.3
 Range0.3–33.5
Time since first metastatic disease, months
 Median14.8
 Range2.3–168.9
PD-L1 expression (≥1% of tumor cells), n (%)
 Positive19 (37.3)
 Negative20 (39.2)
 Not evaluable12 (23.5)
Number of prior lines of therapy for metastatic or locally advanced disease, n (%)
 01 (2.0)
 123 (45.1)
 217 (33.3)
  ≥39 (18.0)
 Missing1 (2.0)
 Median (range)2 (0–4)
Prior anticancer therapy in >5% of patients, n (%)
 Ipilimumab26 (51.0)
 Dacarbazine11 (21.6)
 Cisplatin8 (15.7)
 Interferon6 (11.8)
 Fotemustine5 (9.8)
 Gemcitabine5 (9.8)
 Treosulfan5 (9.8)
 Vemurafenib5 (9.8)
 Investigational drug4 (7.8)
 Paclitaxel3 (5.9)
 Sorafenib3 (5.9)

a Includes melanoma of the canthus (n = 1) and unknown primary (n = 4)